We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Muzaffar Qazilbash

Muzaffar H. Qazilbash MD

Professor of Medicine and Director, Myeloma Transplantation and Cellular Therapy, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas

Muzaffar H. Qazilbash, MD, is a Professor in the Department of Stem Cell Transplantation and Cellular Therapy at UT MD Anderson Cancer Center, which he joined in October 2002. He completed his hematology-oncology fellowship at the National Institutes of Health (NIH) in Bethesda, Maryland. Dr. Qazilbash's clinical and research work has been focused on improving the outcomes of stem cell transplantation and cellular therapy for patients with multiple myeloma and related disorders.

As Director of Myeloma Transplantation and Cellular Therapy in the Department of Stem Cell Transplantation and Cellular Therapy, Dr. Qazilbash leads one of the largest myeloma transplant programs in the country. He has led several clinical trials for myeloma and related disorders, funded by the NIH and various philanthropic organizations. He has served as the Principal Investigator for the idiotype vaccine and cellular therapy studies (2004-0660, 2010- 0710) for myeloma, funded by the National Cancer Institute (SPORE) and the Leukemia Lymphoma Society (SCOR). He also led the PR1 vaccine trial (DM97-325), an NCI-sponsored study (# T98-0017) that received national recognition due to its novel approach and encouraging results.

Dr. Qazilbash has authored or co-authored more than 220 articles in peer-reviewed medical journals and serves in leadership positions at various institutional and extramural committees. He has been invited to present his work at many national and international symposia. He also leads the Clinical Research Committee within the Department of Stem Cell Transplantation, and serves as a member of the Advisory Council of Clinical Research Leaders at the MD Anderson Cancer Center.